Who we are
DEBx Medical B.V. is a Dutch medical technology company dedicated to revolutionizing the management of chronic wounds by enabling their healing, thereby improving the outcomes for millions of patients. DEBx Medical aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed. Our core values focus on delivering affordable treatments that are easy to use and implement in daily clinical practice.
1-2%
Population
Chronic wounds affect approximately 1-2 % of the general population in developed countries with different healing outcomes based on the wound size and etiology of the wound. Often disguised as a comorbid condition, chronic wounds represent a silent epidemic that affect a large fraction of the world’s population.
billion usd
The expected global value of the chronic wound care market by 2027 is 16,36 billion USD. Increasing costs of health care, an aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide make chronic wounds a substantial clinical, social, and economic challenge.
Chronic wounds
A biofilm is present in 78 % of all wounds. This is a thin layer of glycoproteic material from actively replicating bacteria that adheres to the lesion and results in recurring infections, preventing the wound from healing.
Our Team
Roderick Janssen
Jim Damen
Lorem Ipsum
Lorem Ipsum
Lorem Ipsum
Lorem Ipsum
Chronic wounds: The silent epidemic
Globally, millions of people suffer from chronic wounds. Patients face devastating consequences such as experience severe pain and distress, reduced mobility, and a sense of isolation. Also societies and public healthcare systems are challenged by rising costs due to the increasing number of patients and a lack of effective treatment solutions.
Wounds are defined as chronic when they have not healed, at least in part, after 4 to 12 weeks. One reason for becoming chronic is that an infection or a biofilm is present inside the wound bed that prevents the natural healing process. Current methods fail to effectively battle these infections and therefore mainly focus on reducing patients’ discomfort rather than healing the wound.
These methods require an approach in which different treatments must be applied simultaneously before being effective. This results in high costs and a time-consuming process, without an actual perspective for the patient.
DEBx Medical is on track to deliver better and less inconvenient chronic wound treatments globally. Our first product, DEBRICHEM, removes the infection in a chronic wound in just 60 seconds.
Our aim is to become and stay the leading company in the field. To this end, we continuously invest in research and development and are working hard to expand our product line to supply different products for every phase in wound care. We aspire a comprehensive portfolio ranging from diagnosis and treatment of the infection in chronic wounds to aftercare and the maintenance of a healthy wound bed.
